DMT
Common Names: N-Dimethyltryptamine, N-DMT, Dmitri, The, Spirit
Psychoactive Effects
Positive Effects
- Euphoria
Neutral Effects
- Intense visual hallucinations
- Complete reality replacement
- Entity encounters
- Time dilation/compression
- Ego dissolution
- Transcendental experiences
Negative Effects
- Anxiety
- Fear
Dosage Guidelines
| Route | Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|---|
| Smoked | 2-5 mg | 5-15 mg | 15-30 mg | 30-50 mg | 50+ mg |
| Oral | 20-50 mg | 50-100 mg | 100-200 mg | 200-300 mg | 300+ mg |
Note: DMT is naturally occurring in many plants and animals. When taken orally, it requires a monoamine oxidase inhibitor (MAOI) to be active. The experience is often described as the most intense psychedelic experience possible.
Duration
| Phase | Duration |
|---|---|
| Onset | Immediate (smoked) |
| Peak | 2-5 minutes |
| Total | 5-15 minutes |
| After effects | 15-30 minutes |
Pharmacology
Mechanism of Action: DMT acts as a partial agonist at serotonin 5-HT2A receptors, similar to other classical psychedelics. It also has affinity for 5-HT1A, 5-HT2B, 5-HT2C, and sigma-1 receptors.
Metabolism: Rapidly metabolized by monoamine oxidase (MAO) enzymes, particularly MAO-A. When taken orally, it requires MAO inhibitors to prevent rapid breakdown.
Half-life: Very short, approximately 10-15 minutes when smoked/vaporized.
Bioavailability: ~50% when smoked/vaporized, but essentially 0% when taken orally without MAO inhibitors due to rapid metabolism.
Risks and Harm Reduction
⚠️ Important: Always practice harm reduction. Start with low doses, test your substances, and ensure a safe set and setting. Never use alone.
Legal Status
Disclaimer: Legal status varies by jurisdiction and may change. This information is for educational purposes only.
References
- • Strassman, R. J. (2001). DMT: The Spirit Molecule. Park Street Press.
- • Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355.
- • Carbonaro, T. M., & Gatch, M. B. (2016). Neuropharmacology of N,N-dimethyltryptamine. Brain Research Bulletin, 126, 74-88.
- • McKenna, D. J., et al. (1984). Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca. Journal of Ethnopharmacology, 10(2), 195-223.
- • Information compiled from PsychonautWiki